Patient-Reported Outcome Study of Project ECHO for ILD

Sponsor
Pulmonary Care and Research Collaborative Limited (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05450276
Collaborator
Genentech, Inc. (Industry)
56
1
20
2.8

Study Details

Study Description

Brief Summary

The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will employ nested mixed-method design at baseline, at 6 months and at 12 months to answer the study question.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Project ECHO (Extension for Community Healthcare Outcomes) is a knowledge-sharing model to expand the capacity of the health care workforce so that more people can get high quality care for their health conditions in or near the communities where they live. The model brings specialty disease expertise to community providers through its hub-and-spoke networks. The model relies on videoconferencing to connect local providers in non-urban or underserved communities (spoke sites) with an interdisciplinary team of specialist providers at academic medical centers (hubs) during virtual "teleECHO" clinic sessions, which include brief educational lectures and case-based, experiential learning.

    The ECHO model addresses barriers of long wait times for a first appointment, the time and expense associated with long distance travel, and the disinclination to follow through on repeated care appointments in the face of these persistent barriers, all with the additional objective of achieving health equity. Most patients perceive the diagnostic and care pathways in ILDs as a major struggle because of lack of awareness about the diseases, delayed access to specialty centers, providers' focus on disease- versus patient-centered care, and lack of reliable information and education about the diseases and supportive care resources.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    56 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Patient-Reported Outcome Study of Project ECHO for ILD
    Anticipated Study Start Date :
    Jul 1, 2022
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Mar 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Change in patients' stress level [Up to 18 months]

      Assessed by the Perceived Stress Scale at baseline, 6 months, and at study end. The range of scores is 0-40, with higher scores indicating more appraised stress.

    2. Patients' satisfaction of care [Up to 18 months]

      Assessed by the Patient Satisfaction Survey, a self-report scale assessing patient experience and satisfaction with local ILD care, which is composed of 28 items rated on a Likert Scale and Yes/No grading; the summed items produce a single satisfaction score.

    Secondary Outcome Measures

    1. Change in patients' perceptions regarding local ILD care [Up to 18 months]

      Patient participants in the study will complete interviews at baseline (their community PCP or pulmonologist attending their first ILD teleECHO clinic), at 6 months and at 12 months. The interviews will be open-ended to solicit the perspectives of participants regarding their experience with the local ILD care in their communities before, during and after their PCPs or local pulmonologists participate in Project ECHO for ILD.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Confirmed diagnosis of interstitial lung disease

    • Not be currently followed by an ILD specialist at an academic institution or must live more than 50 miles away from an academic ILD center

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Pulmonary Care and Research Collaborative, Ltd. Boston Massachusetts United States 02130

    Sponsors and Collaborators

    • Pulmonary Care and Research Collaborative Limited
    • Genentech, Inc.

    Investigators

    • Principal Investigator: Aliaa Barakat, PhD, Pulmonary Care and Research Collaborative, Ltd.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Pulmonary Care and Research Collaborative Limited
    ClinicalTrials.gov Identifier:
    NCT05450276
    Other Study ID Numbers:
    • ILDC-003
    First Posted:
    Jul 8, 2022
    Last Update Posted:
    Jul 8, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Pulmonary Care and Research Collaborative Limited
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 8, 2022